Identifying Predictors of Anti-VEGF Treatment Response in Patients with Neovascular Age-Related Macular Degeneration through Discriminant and Principal Component Analysis

被引：6

作者：

Holz, Frank G. ^{[1
]}

Tadayoni, Ramin ^{[3
]}

Beatty, Stephen ^{[4
]}

Berger, Alan R. ^{[5
,6
]}

Cereda, Matteo G. ^{[7
]}

Hykin, Philip ^{[8
]}

Hoyng, Carel B. ^{[10
]}

Wittrup-Jensen, Kim ^{[2
]}

Altemark, Andreas ^{[2
]}

Nilsson, Jonas ^{[11
]}

Kim, Kun ^{[12
]}

Sivaprasad, Sobha ^{[8
,9
]}

机构：

[1] Univ Bonn, Dept Ophthalmol, Bonn, Germany

[2] Bayer Pharmaceut, Berlin, Germany

[3] Univ Paris 07, Hop Lariboisiere, AP HP, Dept Ophthalmol,Sorbonne Paris Cite, Paris, France

[4] Inst Eye Surg, Dept Ophthalmol, Waterford, Ireland

[5] Univ Toronto, Dept Ophthalmol & Vis Sci, Toronto, ON, Canada

[6] St Michaels Hosp, Toronto, ON, Canada

[7] Univ Milan, Luigi Sacco Hosp, Dept Biomed & Clin Sci Luigi Sacco, Milan, Italy

[8] Moorfields Eye Hosp, NIHR Biomed Ctr Res Ophthalmol, London, England

[9] Kings Coll Hosp London, Dept Ophthalmol, London, England

[10] Radboud Univ Nijmegen Med Ctr, Dept Ophthalmol, Nijmegen, Netherlands

[11] Real World Strategy & Analyt, Mapi Grp, Stockholm, Sweden

[12] AstraZeneca Nord Balt, Hlth Econ, Sodertalje, Sweden

来源：

OPHTHALMIC RESEARCH | 2017年 / 58卷 / 01期

关键词：

AURA; Intravitreal ranibizumab; Neovascular age-related macular degeneration; INTRAVITREAL RANIBIZUMAB; VISUAL-ACUITY; OUTCOMES; LIFE; AMD;

D O I：

10.1159/000449001

中图分类号：

R77 [眼科学];

学科分类号：

100212 ;

摘要：

Objective: AURA was an observational study that monitored visual acuity outcomes following ranibizumab use in neovascular age-related macular degeneration patients over 2 years. The aim of this analysis was to identify factors that were predictive of visual acuity outcomes in AURA. Methods: The correlation between the baseline characteristics, the use of resources and the visual acuity outcomes in AURA was explored using principal component analysis (PCA) and partial least-squares-discriminant analysis (PLS-DA). The response variables analysed were mean change in visual acuity over 2 years (analysed via PCA) and no decline in visual acuity at 2 years compared with baseline (analysed via PLS-DA). Results: The AURA dataset comprised 2,227 patients and 132 variables. Using PCA and PLS-DA, we found that the number of ranibizumab injections, clinic and monitoring visits, number of optical coherence tomography scans and ophthalmoscopies correlated with a change in visual acuity at Years 1 and 2, and are therefore key drivers of treatment success. Conclusion: This is a novel approach to graphically explore relationships between multiple correlated covariates and outcomes in real-life ophthalmology studies. It identified a number of variables that are positively linked with treatment outcomes. (C) 2016 S. Karger AG, Basel

引用

页码：49 / 55

页数：7

共 13 条

[1] Predictors of 1-year visual outcome in neovascular age-related macular degeneration following intravitreal ranibizumab treatment [J].